In conclusion, FSTL1 overexpression could counteract the effects of skeletal muscle IRF4 ablation in steatosis, fibrosis, and inflammation in NASH mice. This evidence concerns the gene FSTL1 and metabolic dysfunction-associated steatohepatitis.